Green Planet Bioengineering Co Financials
This page shows Green Planet Bioengineering Co (GPLB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Green Planet Bioengineering’s reported pattern is a recurring overhead burn financed by matching small capital infusions, not operating cash generation.
Operating cash burn stayed very close to the net loss across FY2023-FY2025, ending at-$37K versus-$36K in FY2025, while financing inflows repeatedly arrived in similar amounts. That pairing implies the reported losses are mostly cash overhead, so outside funding appears to be covering routine expenses rather than investment-heavy expansion.
The balance-sheet fragments point to no working-capital buffer: FY2025 shows
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
Green Planet Bioengineering Co does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Green Planet Bioengineering Co reported a net loss of $36K while operations used $37K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Green Planet Bioengineering Co reported -$36K in net income in fiscal year 2025. This represents a decrease of 0.8% from the prior year.
Green Planet Bioengineering Co earned $0.00 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Green Planet Bioengineering Co held $0 in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
None of these metrics is reported for fiscal year 2025.
GPLB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SG&A Expenses | N/A | $36K+0.8% | $36K-25.0% | $47K+45.6% | $33K-1.2% | $33K-2.0% | $34K+32.5% | $25K-37.0% | $40K+18.9% | $34K-5.1% | $36K+8.0% | $33K-12.0% | $38K+9.0% | $34K-20.9% | $43K | N/A |
| Interest Expense | N/A | $0 | $0-100.0% | $300 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| Net Income | N/A | -$36K-0.8% | -$36K+25.4% | -$48K-46.5% | -$33K+1.2% | -$33K+2.0% | -$34K-32.5% | -$25K+37.0% | -$40K-18.9% | -$34K+5.1% | -$36K-8.0% | -$33K+12.0% | -$38K-9.0% | -$34K+20.9% | -$43K | N/A |
| EPS (Diluted) | — | $0.00 | $0.00 | $0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, Operating Income.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
GPLB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $668 |
| Current Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $668 |
| Cash & Equivalents | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $668 |
| Total Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $258K+18.5% | $217K+18.5% | $183K+24.1% | $148K+28.8% | $115K+48.6% | $77K+80.3% | $43K-76.0% | $179K |
| Current Liabilities | $501K+7.7% | $465K+8.3% | $430K+12.5% | $382K+9.3% | $349K+10.4% | $316K+11.9% | $283K+9.8% | $258K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$501K-7.7% | -$465K-8.3% | -$430K-12.5% | -$382K-9.3% | -$349K-10.4% | -$316K-11.9% | -$283K-9.8% | -$258K-18.5% | -$217K-18.5% | -$183K-24.1% | -$148K-28.8% | -$115K-48.6% | -$77K-80.3% | -$43K+75.9% | -$178K |
| Retained Earnings | -$1.1M-3.3% | -$1.1M-3.4% | -$1.1M-4.7% | -$1.0M-3.3% | -$979K-3.5% | -$946K-3.7% | -$912K-2.9% | -$887K-4.8% | -$847K-4.2% | -$813K-4.6% | -$777K-4.4% | -$744K-5.3% | -$707K-5.1% | -$672K-6.9% | -$629K |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
GPLB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$53K | -$37K-4.3% | -$35K+17.9% | -$43K-31.2% | -$33K+1.2% | -$33K+2.6% | -$34K+8.4% | -$37K+8.3% | -$40K | $0 | $0 | $0 | $0 | $0+100.0% | -$668 | N/A |
| Investing Cash Flow | N/A | N/A | $35K-17.9% | $43K | $0 | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| Financing Cash Flow | $53K | $37K+4.3% | $35K-17.9% | $43K+31.2% | $33K-1.2% | $33K-2.6% | $34K-8.4% | $37K-8.3% | $40K | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
GPLB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Debt-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$501K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where Green Planet Bioengineering Co Ranks
Frequently Asked Questions
Is Green Planet Bioengineering Co profitable?
No, Green Planet Bioengineering Co (GPLB) reported a net income of -$36K in fiscal year 2025.
What is Green Planet Bioengineering Co's operating cash flow?
Green Planet Bioengineering Co (GPLB) recorded an outflow of $37K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What is Green Planet Bioengineering Co's current ratio?
Green Planet Bioengineering Co (GPLB) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Green Planet Bioengineering Co's cash runway?
Based on fiscal year 2025 data, Green Planet Bioengineering Co (GPLB) had $0 in cash against an annual operating cash burn of $37K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Green Planet Bioengineering Co's debt-to-equity ratio negative or not reported?
Green Planet Bioengineering Co (GPLB) has negative shareholder equity of -$501K as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Are Green Planet Bioengineering Co's earnings high quality?
Green Planet Bioengineering Co (GPLB) reported a net loss of $36K while operations used $37K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.